Project/Area Number |
20590403
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Experimental pathology
|
Research Institution | National Institute of Infectious Diseases |
Principal Investigator |
OKUMA Kazu National Institute of Infectious Diseases, 血液・安全性研究部, 室長 (80315085)
|
Co-Investigator(Kenkyū-buntansha) |
TANAKA Yuetsu 琉球大学, 免疫学講座, 教授 (30163588)
FUJITA Jiro 琉球大学, 感染病態制御学講座, 教授 (80209056)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2008: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | ヒト免疫不全ウイルス1型 / エイズ / 新規治療薬 / 感染実験動物モデル / ヒト化マウス |
Research Abstract |
As candidates for novel drugs to control AIDS/human immunodeficiency virus type 1 (HIV-1) infection, a recombinant vesicular stomatitis virus (VSV) expressing HIV-1 receptors and CXCR4 antagonist were evaluated. In vitro and in immunodeficient mice transplanted with human peripheral blood mononuclear cells or with human hematopoietic stem cells (humanized mice), both candidates could inhibit HIV-1 infection definitely, indicating that they have a potentially therapeutic value for AIDS/HIV-1 infection.
|